Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120

Virology

Volumn 321, Issue 1, 2004, Pages 75-86

  Berkower, Ira ^a   Raymond, Megan ^a   Muller, Jacqueline ^a   Spadaccini, Angelo ^a   Aberdeen, Anne ^a  

^a Center for Biologics   (United States)

Author keywords

Envelope glycoprotein gp120; HIV 1; Virus like particles

Indexed keywords

CARRIER PROTEIN; GLYCOPROTEIN GP 120; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; LIPID COMPOSITION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONTENT; PROTEIN MICROARRAY; VIRION; VIRUS ASSEMBLY; VIRUS MORPHOLOGY; VIRUS PARTICLE;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; BASE SEQUENCE; EPITOPE MAPPING; HEPATITIS B SURFACE ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNIZATION; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; RABBITS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VACCINIA VIRUS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 1642349618     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2003.12.017     Document Type: Article

References (63)

1. Aggerbeck L., Peterson D. Electron microscopic and solution X-ray scattering observations on the structure of hepatitis B surface antigen. Virology. 141:1985;155-161.
2. Arthur L.O., Bess J.W. Jr., Chertova E.N., Rossio J.L., Esser M.T., Benveniste R.E., Henderson L.E., Lifson J.D. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res. Hum. Retroviruses. 14(Suppl. 3):1998;S311-S319.
3. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., Ruprecht R.M. Human neutralizing antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:2000;200-206.
4. Bachmann M.F., Zinkernagel R.M. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15:1997;235-270.
5. Berkower I., Smith G.E., Giri C., Murphy D. Human immuno-deficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation. J. Exp. Med. 170:1989;1681-1695.
6. Berkower I., Murphy D., Smith C.C., Smith G.E. A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120. J. Virol. 65:1991;5983-5990.
7. Berkower I., Mostowski H., Bull T.E., Murphy D. CD4-IgG binding threshold for inactivation of human immunodeficiency virus type 1. J. Infect. Dis. 173:1996;863-869.
8. Bisht H., Chugh D.A., Raje M., Swaminathan S.S., Khanna N.J. Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen. J. Biotechnol. 99:2002;97-110.
9. Bruss V., Ganem D. Mutational analysis of hepatitis B surface antigen particle assembly and secretion. J. Virol. 65:1991;3813-3820.
10. Buchacher A., Predl R., Tauer C., Purtscher M., Gruber G., Heider R., Steindl F., Trkola A., Jungbauer A., Katinger H. Vaccines. 92:1992;191-195.
11. Burton D.R., Barbas C.F., Persson M.A., Koenig S., Chanock R.M., Lerner R.A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. U.S.A. 88:1991;10134-10137.
12. Cabral G.A., Marciano-Cabral F., Funk G.A., Sanchez Y., Hollinger F.B., Melnick J.L., Dreesman G.R. Cellular and humoral immunity in guinea pigs to two major polypeptides derived from hepatitis B surface antigen. J. Gen. Virol. 38:1978;339-350.
13. Capon D.J., Chamow S.M., Mordenti J., Marsters S.A., Gregory T., Mitsuya H., Byrn R.A., Lucas C., Wurm F.M., Groopman J.E.et al. Designing CD4 immunoadhesins for AIDS therapy. Nature. 337:1989;525-531.
14. Cheng K.C., Moss B. Selective synthesis and secretion of particles composed of the hepatitis B virus middle surface protein directed by a recombinant vaccinia virus: induction of antibodies to pre-S and S epitopes. J. Virol. 61:1987;1286-1290.
15. Chertova E., Bess J.W. Jr., Crise B.J., Sowder R.C., Schaden T.M., Hilburn J.M., Hoxie J.A., Benveniste R.E., Lifson J.D., Henderson L.E., Arthur L.O. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76:2002;5315-5325.
16. Chow Y.H., Huang W.L., Chi W.K., Chu Y.D., Tao M.H. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 71:1997;169-178.
17. Cochran M.A., Ericson B.L., Knell J.D., Smith G.E. Chanock R.M., Lerner R.A., Brown F., Ginsberg H. Vaccines '87. 1987;384-388 Cold Spring Harbor Press, NY.
18. Connor R.I., Chen B.K., Choe S., Landau N.R. Vpr Is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology. 206:1995;935-944.
19. Delpeyroux F., Chenciner N., Lim A., Malpiece Y., Blondel B., Crainic R., van der Werf S., Streeck R.E. A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science. 233:1986;472-475.
20. Earl, P.L., Moss, B., 1991. Generation of recombinant vaccinia viruses, In: Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., Struhl, K. (Ed.), Current Protocols in Molecular biology, vol. 2. Greene Publishing Associates and Wiley Inter-science, New York, pp. 16.17.1-16.17.16.
21. Earl P.L., Broder C.C., Long D., Lee S.A., Peterson J., Chakrabarti S., Doms R.W., Moss B. Native oligomeric forms of human immunodeficiency virus type 1 envelope glycoprotein elicit a diverse array of monoclonal antibody reactivities. J. Virol. 68:1994;3015-3026.
22. Earl P.L., Sugiura W., Montefiori D.C., Broder C.C., Lee S.A., Wild C., Lifson J., Moss B. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J. Virol. 75:2001;645-653.
23. Eble B.E., MacRae D.R., Lingappa V.R., Ganem D. Multiple topogenic sequences determine the transmembrane orientation of the hepatitis B surface antigen. Mol. Cell. Biol. 7:1987;3591-3601.
24. Eckhart L., Raffelsberger W., Ferko B., Klima A., Purtscher M., Katinger H., Ruker F. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J. Gen. Virol. 77:1996;2001-2008.
25. Ganem D., Schneider R.J. Hepadnaviridae: the viruses and their replication. Knipe E.M., Howley P.M., Griffin D.E., Martin M.A., Lamb R.A., Roizman B., Straus S.E. Field's Virology. 4th ed. 2001;2923-2969 Lippincott, Williams and Wilkins, Philadelphia.
26. Gerhardt E., Bruss V. Phenotypic mixing of rodent but not avian hepadnavirus surface proteins into human hepatitis B virus particles. J. Virol. 69:1995;1201-1208.
27. Graham B.S., Keefer M.C., McElrath J., Gorse G.J., Schwartz D.H., Weinhold K., Matthews T.J., Esterlitz J.R., Sinangil F., Fast P.E. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann. Intern. Med. 125(4):1996;270-279.
28. Grene E., Mezule G., Borisova G., Pumpens P., Bentwich Z., Arnon R. Relationship between antigenicity and immunogenicity of chimeric hepatitis B virus core particles carrying HIV type 1 epitopes. AIDS Res. Hum. Retroviruses. 13:1997;41-51.
29. Haas J., Park E.-C., Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6:1996;315-324.
30. Healey D., Dianda L., Moore J.P., McDougal J.S., Moore M.J., Estess P., Buck D., Kwong P.D., Beverley P.C., Sattentau Q.J. Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. J. Exp. Med. 172:1990;1233-1242.
31. Huovila A.-P.J., Eder A.M., Fuller S.D. Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment. J. Cell Biol. 118:1992;1305-1320.
32. Kingsman A.J., Burns N.R., Layton G.T., Adams S.E. Yeast retrotransposon particles as antigen delivery systems. Ann. N. Y. Acad. Sci. 754:1995;202-213.
33. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U.S.A. 89:1992;12180-12184.
34. Kowalski M., Potz J., Basiripour L., Dorfman T., Goh W.C., Terwilliger E., Dayton A., Rosen C., Haseltine W., Sodroski J. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science. 237:1987;1351-1355.
35. Li A., Baba T.W., Sodroski J., Zolla-Pazner S., Gorny M.K., Robinson J., Posner M.R., Katinger H., Barbas C.F. III, Burton D.R., Chou T.C., Ruprecht R.M. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res. Hum. Retroviruses. 13:1997;647-656.
36. Liu X.S., Liu W.J., Zhao K.N., Liu Y.H., Leggatt G., Frazer I.H. Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. Immunol. Cell Biol. 80:2002;21-29.
37. Lu S., Santoro J.C., Fuller D.H., Haynes J.R., Robinson H.L. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology. 209:1995;147-154.
38. Luckow V.A., Lee C.S., Barry G.F., Olins P.O. Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli. J. Virol. 67:1993;4566-4579.
39. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., Clements M.L., Dolin R., Graham B.S., Gorse G.J., Keefer M.C., McElrath M.J., Walker M.C., Wagner K.F., McNeil J.G., McCutchan F.E., Burke D.S. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173:1996;340-348.
40. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:2000;207-210.
41. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:1993;6642-6647.
42. Otteken A., Earl P.L., Moss B. Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. J. Virol. 70:1996;3407-3415.
43. Pal R., di Marzo Veronese F., Nair B.C., Rahman R., Hoke G., Mumbauer S.W., Sarngadharan M.G. Characterization of a neutralizing monoclonal antibody to the external glycoprotein of HIV-1. Intervirology. 34:1992;86-93.
44. Patterson L.J., Aberdeen A., Kone J., Haben M., Raymond M., Berkower I. Formation of HIV-1 envelope-hepatitis B core antigen hybrids with high affinity for CD4. Biochem. Biophys. Res. Commun. 285:2001;639-643.
45. Piza A., Pieri K., Lusa G., Caporale G., Terreran M., Machado L., Zanetti C. Effect of the contents and form of rabies glycoprotein on the potency of rabies vaccination in cattle. Mem. Inst. Oswaldo Cruz. 97:2002;265-268.
46. Poignard P., Saphire E.O., Parren P.W., Burton D.R. gp120: biologic aspects of structural features. Annu. Rev. Immunol. 19:2001;253-274.
47. Pollard S.T., Rosa M.D., Rosa J.J., Wiley D.C. Truncated variants of gp120 bind CD4 with high affinity and suggest a minimum CD4 binding region. EMBO J. 11:1992;585-591.
48. Posner M.R., Cavacini L.A., Emes C.L., Power J., Byrn R. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J. AIDS. 6:1993;7-14.
49. Rizzetto M., Hoyer B., Canese M.G., Shih J.W., Purcell R.H., Gerin J.L. delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc. Natl. Acad. Sci. U.S.A. 77:1980;6124-6128.
50. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., Montefiori D., Roberts A., Buonocore L., Rose J.K. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 106:2001;539-549.
51. Sonveaux N., Conrath K., Capiau C., Brasseur R., Goormaghtigh E., Ruysschaert J.-M. The topology of the S protein in the yeast-derived hepatitis B surface antigen particles. J. Biol. Chem. 269:1994;25637-25645.
52. Steimer K.S., Scandella C.J., Skiles P.V., Haigwood N.L. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science. 254:1991;105-108.
53. Stemmer W.P.C., Crameri A., Ha K.D., Brennan T.M., Heyneker H.L. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene. 164:1995;49-53.
54. Stirk H.J., Thornton J.M., Howard C.R. A topological model for hepatitis B surface antigen. Intervirology. 33:1992;148-158.
55. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., Wellde B.T., Garcon N., Krzych U., Marchand M. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336:1997;86-91.
56. Thali M., Olshevsky U., Furman C., Gabuzda D., Posner M., Sodroski J. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J. Virol. 65:1991;6188-6193.
57. Tobin G.J., Nagashima K., Gonda M.A. Immunologic and ultrastructural characterization of HIV pseudovirions containing gag and Env precursor proteins engineered in insect cells. Methods. 10:1996;208-218.
58. Valenzuela P., Coit D., Medina-Selby M.A., Kuo C.H., Van Nest G., Burke R.L., Bull P., Urdea M.S., Graves P.V. Biotechnology. 3:1985;323-326.
59. Wagner R., Teeuwsen V.J., Deml L., Notka F., Haaksma A.G., Jhagjhoorsingh S.S., Niphuis H., Wolf H., Heeney J.L. Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection. Virology. 245:1998;65-74.
60. Watanabe M.E. Skeptical scientists skewer VaxGen statistics. Nat. Med. 9:2003;376.
61. Weiss C.D., Levy J.A., White J.M. Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J. Virol. 64:1990;5674-5677.
62. Willey R.W., Byrum R., Piatak M., Kim Y.B., Cho M.W., Rossio J.L. Jr., Bess J. Jr., Igarashi T., Endo Y., Arthur L.O., Lifson J.D., Martin M.A. Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles. J. Virol. 77:2003;1163-1174.
63. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., Sodroski J.G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393:1998;705-711.